Cargando…

Evaluation of two strategies for the interpretation of tumour markers in pleural effusions

BACKGROUND: Pleural effusions present a diagnostic challenge. Approximately 20% are associated with cancer and some 50% require invasive procedures to perform diagnosis. Determination of tumour markers may help to identify patients with malignant effusions. Two strategies are used to obtain high spe...

Descripción completa

Detalles Bibliográficos
Autores principales: Trapé, Jaume, Sant, Francesc, Franquesa, Josefina, Montesinos, Jesús, Arnau, Anna, Sala, Maria, Bernadich, Oscar, Martín, Esperanza, Perich, Damià, Pérez, Concha, Lopez, Joan, Ros, Sandra, Esteve, Enrique, Pérez, Rafael, Aligué, Jordi, Gurt, Gabriel, Catot, Silvia, Domenech, Montserrat, Bosch, Joan, Badal, Josep Miquel, Bonet, Mariona, Molina, Rafael, Ordeig, Josep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5445332/
https://www.ncbi.nlm.nih.gov/pubmed/28545517
http://dx.doi.org/10.1186/s12931-017-0582-1
_version_ 1783238865052499968
author Trapé, Jaume
Sant, Francesc
Franquesa, Josefina
Montesinos, Jesús
Arnau, Anna
Sala, Maria
Bernadich, Oscar
Martín, Esperanza
Perich, Damià
Pérez, Concha
Lopez, Joan
Ros, Sandra
Esteve, Enrique
Pérez, Rafael
Aligué, Jordi
Gurt, Gabriel
Catot, Silvia
Domenech, Montserrat
Bosch, Joan
Badal, Josep Miquel
Bonet, Mariona
Molina, Rafael
Ordeig, Josep
author_facet Trapé, Jaume
Sant, Francesc
Franquesa, Josefina
Montesinos, Jesús
Arnau, Anna
Sala, Maria
Bernadich, Oscar
Martín, Esperanza
Perich, Damià
Pérez, Concha
Lopez, Joan
Ros, Sandra
Esteve, Enrique
Pérez, Rafael
Aligué, Jordi
Gurt, Gabriel
Catot, Silvia
Domenech, Montserrat
Bosch, Joan
Badal, Josep Miquel
Bonet, Mariona
Molina, Rafael
Ordeig, Josep
author_sort Trapé, Jaume
collection PubMed
description BACKGROUND: Pleural effusions present a diagnostic challenge. Approximately 20% are associated with cancer and some 50% require invasive procedures to perform diagnosis. Determination of tumour markers may help to identify patients with malignant effusions. Two strategies are used to obtain high specificity in the differential diagnosis of malignant pleural effusions: a) high cut-off, and b) fluid/serum (F/S) ratio and low cut-off. The aim of this study is to compare these two strategies and to establish whether the identification of possible false positives using benign biomarkers – ADA, CRP and % of polymorphonuclear cells – improves diagnostic accuracy. METHODS: We studied 402 pleural effusions, 122 of them malignant. Benign biomarkers were determined in pleural fluid, and CEA, CA72-4, CA19-9 and CA15-3 in pleural fluid and serum. RESULTS: Establishing a cut-off value for each TM for a specificity of 100%, a joint sensitivity of 66.5% was obtained. With the F/S strategy and low cut-off points, sensitivity was 77% and specificity 98.2%, Subclassifying cases with negative benign biomarkers, both strategies achieved a specificity of 100%; sensitivity was 69.9% for single determination and 80.6% for F/S ratio. CONCLUSIONS: The best interpretation of TM in the differential diagnosis of malignant pleural effusions is obtained using the F/S ratio in the group with negative benign biomarkers.
format Online
Article
Text
id pubmed-5445332
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54453322017-05-30 Evaluation of two strategies for the interpretation of tumour markers in pleural effusions Trapé, Jaume Sant, Francesc Franquesa, Josefina Montesinos, Jesús Arnau, Anna Sala, Maria Bernadich, Oscar Martín, Esperanza Perich, Damià Pérez, Concha Lopez, Joan Ros, Sandra Esteve, Enrique Pérez, Rafael Aligué, Jordi Gurt, Gabriel Catot, Silvia Domenech, Montserrat Bosch, Joan Badal, Josep Miquel Bonet, Mariona Molina, Rafael Ordeig, Josep Respir Res Research BACKGROUND: Pleural effusions present a diagnostic challenge. Approximately 20% are associated with cancer and some 50% require invasive procedures to perform diagnosis. Determination of tumour markers may help to identify patients with malignant effusions. Two strategies are used to obtain high specificity in the differential diagnosis of malignant pleural effusions: a) high cut-off, and b) fluid/serum (F/S) ratio and low cut-off. The aim of this study is to compare these two strategies and to establish whether the identification of possible false positives using benign biomarkers – ADA, CRP and % of polymorphonuclear cells – improves diagnostic accuracy. METHODS: We studied 402 pleural effusions, 122 of them malignant. Benign biomarkers were determined in pleural fluid, and CEA, CA72-4, CA19-9 and CA15-3 in pleural fluid and serum. RESULTS: Establishing a cut-off value for each TM for a specificity of 100%, a joint sensitivity of 66.5% was obtained. With the F/S strategy and low cut-off points, sensitivity was 77% and specificity 98.2%, Subclassifying cases with negative benign biomarkers, both strategies achieved a specificity of 100%; sensitivity was 69.9% for single determination and 80.6% for F/S ratio. CONCLUSIONS: The best interpretation of TM in the differential diagnosis of malignant pleural effusions is obtained using the F/S ratio in the group with negative benign biomarkers. BioMed Central 2017-05-25 2017 /pmc/articles/PMC5445332/ /pubmed/28545517 http://dx.doi.org/10.1186/s12931-017-0582-1 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Trapé, Jaume
Sant, Francesc
Franquesa, Josefina
Montesinos, Jesús
Arnau, Anna
Sala, Maria
Bernadich, Oscar
Martín, Esperanza
Perich, Damià
Pérez, Concha
Lopez, Joan
Ros, Sandra
Esteve, Enrique
Pérez, Rafael
Aligué, Jordi
Gurt, Gabriel
Catot, Silvia
Domenech, Montserrat
Bosch, Joan
Badal, Josep Miquel
Bonet, Mariona
Molina, Rafael
Ordeig, Josep
Evaluation of two strategies for the interpretation of tumour markers in pleural effusions
title Evaluation of two strategies for the interpretation of tumour markers in pleural effusions
title_full Evaluation of two strategies for the interpretation of tumour markers in pleural effusions
title_fullStr Evaluation of two strategies for the interpretation of tumour markers in pleural effusions
title_full_unstemmed Evaluation of two strategies for the interpretation of tumour markers in pleural effusions
title_short Evaluation of two strategies for the interpretation of tumour markers in pleural effusions
title_sort evaluation of two strategies for the interpretation of tumour markers in pleural effusions
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5445332/
https://www.ncbi.nlm.nih.gov/pubmed/28545517
http://dx.doi.org/10.1186/s12931-017-0582-1
work_keys_str_mv AT trapejaume evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions
AT santfrancesc evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions
AT franquesajosefina evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions
AT montesinosjesus evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions
AT arnauanna evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions
AT salamaria evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions
AT bernadichoscar evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions
AT martinesperanza evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions
AT perichdamia evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions
AT perezconcha evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions
AT lopezjoan evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions
AT rossandra evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions
AT esteveenrique evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions
AT perezrafael evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions
AT aliguejordi evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions
AT gurtgabriel evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions
AT catotsilvia evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions
AT domenechmontserrat evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions
AT boschjoan evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions
AT badaljosepmiquel evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions
AT bonetmariona evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions
AT molinarafael evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions
AT ordeigjosep evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions